Pyrotinib is a potent epidermal growth factor receptor/human epidermal growth factor receptor 2 (EGFR/HER2) inhibitor and can be used to treat HER2-positive breast cancer (Li et al., 2017; Blair, 2018; Huang et al., 2020). This evidence concerns the gene EGFR and breast carcinoma.